Fig. 1.
The CD4+CD7+:CD4+CD7− ratio of the control group (n = 11) (median 5.78) compared with all B cell chronic lymphocytic leukaemia (B-CLL) patients (n = 21) (median 2.7) (P < 0.0023), stage A patients (n = 12) (median 3.1) (P < 0.009), and stage B/C patients (n = 9) (median 2.06) (P < 0.001). Stage A B-CLL patients compared with stage B/C was not significant (P > 0.37).